UPCC 11423 AGE-ING Assessment of Geriatric Evaluations Impact on New AML Guidance Study (AGE-ING)

Investigating the Impact of Geriatric Evaluations on Acute Myeloid Leukemia Treatment

Enrolling By Invitation
50 years or above
All
Phase N/A
100 participants needed
1 Location

Brief description of study

The goal of the study is to measure physiologic age (there is no current formal definition but is meant to imply that patients should be evaluated holistically rather than on age alone) at baseline in newly diagnosed AML patients over 50 years receiving either intensive or non-intensive treatment. This information will be used to evaluate toxicity, early mortality, remission rates and long term survival.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: AML, Adult
  • Age: 50 years or above
  • Gender: All

Inclusion Criteria:

  • AML diagnosis by peripheral flow cytometry and/or bone marrow aspirate and biopsy
  • New diagnosis being considered for new line of treatment
  • Age ≥ 50 years.
  • Performance status 0,1, and 2

Exclusion Criteria:

  • Inability to understand or unable to sign a written informed consent
  • Unable to fill out questionnaires on their own and/or do not have someone to help complete them

This study investigates the impact of assessing physiologic age in patients newly diagnosed with acute myeloid leukemia (AML) who are 50 years or older. The purpose is to understand how evaluating patients' overall health rather than just their chronological age can affect treatment outcomes such as toxicity, early mortality, remission rates, and long-term survival.

Participants will undergo a comprehensive geriatric evaluation at the start of the study. This involves assessing their overall health, which may include physical exams, questionnaires, and other evaluations to determine their physiologic age. The study will compare outcomes for those receiving either intensive or non-intensive treatment based on these evaluations.

  • Who can participate: Individuals aged 50 years or older with a new diagnosis of acute myeloid leukemia (AML) can participate. They must have a performance status of 0, 1, or 2 and be able to understand and sign an informed consent form.
  • Study details: Participants will be required to complete health assessments and questionnaires. These evaluations will help determine their physiologic age and guide the treatment approach, whether intensive or non-intensive.
Updated on 07 Aug 2025. Study ID: 23-0824
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Abramson Cancer Center Navigator